HUTCHMED (NASDAQ:HCM) Shares Gap Up Following Analyst Upgrade

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) shares gapped up prior to trading on Thursday after Daiwa Securities Group upgraded the stock from a hold rating to a buy rating. The stock had previously closed at $12.04, but opened at $13.60. HUTCHMED shares last traded at $13.7280, with a volume of 145,382 shares.

Several other research analysts have also commented on the company. Weiss Ratings lowered HUTCHMED from a “hold (c-)” rating to a “sell (d)” rating in a research report on Friday, July 31st. Wall Street Zen raised HUTCHMED from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. The Goldman Sachs Group lowered their target price on HUTCHMED from $16.00 to $14.00 and set a “neutral” rating for the company in a research note on Thursday, July 23rd. Morgan Stanley set a $13.60 price target on HUTCHMED in a research report on Thursday, May 28th. Finally, Bank of America decreased their price target on HUTCHMED from $20.00 to $17.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $14.87.

Key Headlines Impacting HUTCHMED

Here are the key news stories impacting HUTCHMED this week:

• Positive Sentiment: HUTCHMED granted GSK exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate for solid tumors. The deal includes a $110 million upfront payment and could generate up to $1.295 billion in total milestone payments, plus royalties. Reuters article
• Positive Sentiment: The partnership validates HUTCHMED’s oncology pipeline through a major global pharmaceutical partner and could provide funding and development support for HMPL-A830. The drug is expected to enter clinical trials in the second half of 2026. HUTCHMED announcement
• Positive Sentiment: Daiwa Securities upgraded HCM from “hold” to “buy.” Panmure and Cavendish also reiterated “buy” ratings, citing the GSK deal and what they view as an overlooked valuation relative to HUTCHMED’s expanding oncology pipeline. Broker responses
• Neutral Sentiment: Management discussed the strategic partnership and licensing arrangement in an investor transcript, providing additional details on HMPL-A830’s development and the collaboration with GSK. Seeking Alpha transcript
• Negative Sentiment: HMPL-A830 remains an experimental therapy, so the milestone value is contingent on successful clinical development, regulatory approvals and commercialization. Investors may therefore continue to weigh substantial drug-development risk despite the sizable headline deal.

Hedge Funds Weigh In On HUTCHMED

A number of institutional investors have recently made changes to their positions in HCM. Renaissance Technologies LLC boosted its stake in shares of HUTCHMED by 3.0% during the 4th quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock valued at $1,798,000 after buying an additional 3,900 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of HUTCHMED by 8.5% in the first quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock worth $1,413,000 after buying an additional 7,342 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in HUTCHMED by 157.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 55,969 shares of the company’s stock valued at $746,000 after acquiring an additional 34,248 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in HUTCHMED by 19.7% in the second quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock valued at $377,000 after acquiring an additional 4,116 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in HUTCHMED by 5.9% during the 3rd quarter. Bank of America Corp DE now owns 21,791 shares of the company’s stock valued at $343,000 after acquiring an additional 1,209 shares during the last quarter. 8.82% of the stock is owned by institutional investors and hedge funds.

HUTCHMED Stock Down 0.1%

The company has a current ratio of 5.64, a quick ratio of 5.50 and a debt-to-equity ratio of 0.06. The company’s fifty day simple moving average is $11.76 and its two-hundred day simple moving average is $12.73.

HUTCHMED (NASDAQ:HCM) last issued its earnings results on Thursday, July 30th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.09). The firm had revenue of $139.14 million for the quarter, compared to analyst estimates of $304.16 million. Equities analysts forecast that HUTCHMED will post 0.33 earnings per share for the current fiscal year.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.